Do you want to join one of the fastest-growing molecular diagnostics companies to help transform prenatal and oncology diagnostics that can affect millions of patient lives?
BillionToOne, ranked at the top 5% of Y Combinator companies with $200M+ in funding from prominent VC firms, has developed a DNA molecular counter that increases the cell-free DNA diagnostics resolution by over 1,000 fold. BillionToOne is launching two new oncology products in the liquid biopsy space based on this technology. This portfolio of oncology products will complement BillionToOne's list of offerings in the pre-natal space, powered by the same technology that allows sensitive detection of fetal DNA from maternal blood, much as it will allow sensitive detection of cancer DNA from a patient's blood.
We are looking a field-based professional Medical Science Liaison (MSL), Oncology with scientific and clinical expertise in oncology to help with the launch of our oncology portfolio of liquid biopsy products. The Medical Science Liaison (MSL), Oncology is a remote position and reports to our Chief Medical Officer.
Responsibilities:
Requirements:
Benefits And Perks:
At BillionToOne, we are proud to offer a combination of a (1) base pay range (actual amount offered is based experience and salary/equity options split that the candidate chooses) (2) generous equity options offering, on top of (3) industry leading company benefits (free healthcare options, 401k match, very generous fully paid paternal leave etc.).
For this position, the base pay range is: $120,000-$180,000 per year.
BillionToOne is an equal opportunity employer. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
BillionToOne’s mission is to revolutionize genetic testing through the development of innovative quantitative diagnostics. BillionToOne's DNA Molecular Counting platform integrates next-generation sequencing technologies with machine learning, w...
28 jobsSubscribe to Rise newsletter